Home » Stocks » Magenta Therapeutics

Magenta Therapeutics, Inc. (MGTA)

Stock Price: $6.69 USD -0.06 (-0.89%)
Updated Oct 27, 2020 1:41 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 322.81M
Revenue (ttm) n/a
Net Income (ttm) -83.32M
Shares Out 48.25M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $6.69
Previous Close $6.75
Change ($) -0.06
Change (%) -0.89%
Day's Open 6.74
Day's Range 6.57 - 6.84
Day's Volume 62,710
52-Week Range 5.76 - 16.19

More Stats

Market Cap 322.81M
Enterprise Value 144.53M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 48.25M
Float 29.18M
EPS (basic) -2.13
EPS (diluted) -2.12
FCF / Share -1.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.60M
Short Ratio 9.39
Short % of Float 5.50%
Beta 2.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.96
Revenue n/a
Operating Income -88.54M
Net Income -83.32M
Free Cash Flow -63.85M
Net Cash 178.28M
Net Cash / Share 3.69
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -28.66%
ROE -47.14%
ROIC -129.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$16.67*
(149.18% upside)
Low
13.0
Current: $6.69
High
22.0
Target: 16.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-82.97-59.96-35.73-9.27
Net Income-76.77-57.52-35.49-9.43
Shares Outstanding37.0118.391.860.15
Earnings Per Share-2.07-3.13-19.12-65.15
Operating Cash Flow-57.10-41.89-22.26-6.53
Capital Expenditures-3.06-7.66-2.20-0.14
Free Cash Flow-60.16-49.55-24.46-6.67
Cash & Equivalents14814451.574.54
Net Cash / Debt14814451.574.54
Assets16215754.4611.34
Liabilities20.3211.674.1420.22
Book Value141146-42.12-8.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Magenta Therapeutics, Inc.
Country United States
Employees 72
CEO Jason Gardner

Stock Information

Ticker Symbol MGTA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MGTA

Description

Magenta Therapeutics, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.